High-performance liquid chromatographic separation of an HIV-1 reverse transcriptase inhibitor and its enantiomer. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


High-performance liquid chromatographic separation of an HIV-1 reverse transcriptase inhibitor and its enantiomer.

J Chromatogr A. 1996 Jul 12;738(2):290-4. Unique Identifier : AIDSLINE MED/96314844
Wang T; Grinberg N; Bicker G; Tway P; Thompson K; Analytical Research Department, Merck Research Laboratories,; Rahway, NJ 07065-0900, USA.

Abstract: This article describes the direct separation of an HIV-1 reverse transcriptase inhibitor and its enantiomer by HPLC on a silica-bonded polyacrylamide (ChiraSpher) column. The column selection was based on specific interactions between the individual enantiomers and the chiral stationary phase. The influence of some chromatographic conditions, such as concentration of the polar modifier in the mobile phase, column flow-rate and column temperature, on column performance was investigated. The separation was applied to the determination of the minor enantiomer in the bulk drug and as low as 0.3% of minor enantiomer was detectable.
Keywords: Binding, Competitive Hydrogen-Ion Concentration HIV-1/*ENZYMOLOGY Quinazolines/CHEMISTRY/*ISOLATION & PURIF/PHARMACOLOGY Reverse Transcriptase Inhibitors/CHEMISTRY/*ISOLATION & PURIF/ PHARMACOLOGY RNA-Directed DNA Polymerase/*DRUG EFFECTS Solvents Stereoisomers Temperature JOURNAL ARTICLEKWDbinding,competitivehydrogen-ionconcentrationhiv-1/KWDenzymologyquinazolines/chemistry/KWDisolation&purif/pharmacologyreversetranscriptaseinhibitors/chemistry/KWDisolation&purif/pharmacologyrna-directeddnapolymerase/KWDdrugeffectssolventsstereoisomerstemperaturejournalarticle
961130
M96B1856

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .